Page 229 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
Sanofi, and serves on the Speaker’s Board for Kite Pharma and Pfizer. PRG has provided consultancy services to Kite/Gilead Pharma and Bristol Myers Squibb (BMS), and served on the Advisory Boards of Pharmacyclics LLC, ADC Therapeutics, Cellectar Biosciences, Ono Pharma, CRISPR therapeutics, IPSEN Biopharma, and Regeneron Pharmaceuticals. HM reports honoraria from Mustang Bio and Bavarian Nordic. AS reports grant funding from Kite Pharma and has provided consultancy services to CRISPR Therapeutics. CU reports honoraria from Takeda and Blueprint. CSS has served as a paid consultant for Kite Pharma, Celgene/BMS, Gamida Cell, Karyopharm Therapeutics, Ono Pharmaceuticals, MorphoSys, CSL Behring, Syncopation Life Sciences, CRISPR Therapeutics, Ipsen Biopharmaceuticals and GSK, and has received research funds for clinical trials from Juno Therapeutics, Celgene/BMS, Bristol-Myers Squibb, Precision Biosciences, Actinium Pharmaceuticals, Sanofi-Genzyme, Cargo Therapeutics, Affimed and NKARTA. MH reports research support / funding from Takeda Pharmaceutical Company, ADC Therapeutics, Spectrum Pharmaceuticals, and Astellas Pharma, consultancy from ADC Therapeutics, Omeros, CRISPR, BMS, Kite, Abbvie, Caribou, and Genmab, and Speaker’s Bureau from ADC Therapeutics, AstraZeneca, BeiGene, Kite, DMC Inc., Genentech, Myeloid Therapeutics, CRISPR, and Autolus. CJL received honoraria and / or consultancy and / or research funding from Incyte, Sanofi, Fresenius Kabi, BMS, Kite, and Kadmon. None of the other authors have any conflicts of interest to disclose.
Contributions
MAJ and MH are responsible for data collection and assembly. MAJ, KWA and MH analyzed the data. SM prepared the first draft. All authors
References
1. Ferreri A, Calimeri T, Cwynarski K, et al. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023;9(1):29.
2. Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140(9):971-979.
3. Bernstein SH, Unger JM, LeBlanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516-The Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-119.
4. Hoang-Xuan K, Deckert M, Ferreri AJM, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2023;25(1):37-53.
5. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
6. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.
7. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852.
8. Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7(1):32-39.
are responsible for the study concept and design, and interpretation of data, helped revise the manuscript, and approved the final version for publication.
Funding
The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20- 1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals Inc.; Adienne SA; Allovir Inc.; Amgen Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co. Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune Inc.; Orca Biosystems Inc.; Pfizer Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV.
Data-sharing statement
For original data, please contact the Corresponding Author.
9. Siddiqi T, Wang X, Blanchard M, et al. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv. 2021;5(20):4059-4063.
10. Frigault M, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022;139(15):2306-2315.
11. Alcantara M, Houillier C, Blonski M, et al. CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network. Blood. 2022;139(5):792-796.
12. Choquet S, Soussain C, Azar N, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real-life results of the LOC network. Am J Hematol. 2024;99(7):1240-1249.
13. Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625-638.
14. Minderman M, Amir A, Kraan W, et al. Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. Blood. 2021;138(13):1194-1197.
15. Epperla N, Feng L, Shah N, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16(1):111.
Haematologica | 110 January 2025
221